Cytological differential diagnosis among adenocarcinoma, epithelial mesothelioma, and reactive mesothelial cells in serous effusions by immunocytochemistry

Diagnostic Cytopathology

Volumn 39, Issue 12, 2011, Pages 900-908

  Su, Xue Ying ^a   Li, Gan Di ^a   Liu, Wei Ping ^a   Xie, Bin ^a   Jiang, Ying Hong ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

immunocytochemistry; malignant epithelial mesothelioma; metastatic adenocarcinoma; reactive mesothelium; serous effusion; cell block

Indexed keywords

ANTIBODY; CALRETININ; CARCINOEMBRYONIC ANTIGEN; PROTEIN BER EP4; PROTEIN DES; PROTEIN EMA; PROTEIN HBME 1; PROTEIN MOC 31; PROTEIN P53; THROMBOMODULIN; TUMOR MARKER; UNCLASSIFIED DRUG; UVOMORULIN;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; ASCITES; CANCER CYTODIAGNOSIS; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; EFFUSION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MALIGNANT MESOTHELIOMA; MESOTHELIUM CELL; METASTASIS; PERICARDIAL EFFUSION; PLEURA EFFUSION; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY;

ADENOCARCINOMA; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ASCITIC FLUID; DIAGNOSIS, DIFFERENTIAL; EPITHELIAL CELLS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MESOTHELIOMA; MIDDLE AGED; PERICARDIAL EFFUSION; PLEURAL EFFUSION, MALIGNANT; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 81255161249     PISSN: 87551039     EISSN: 10970339     Source Type: Journal    
DOI: 10.1002/dc.21489     Document Type: Article

References (32)

1. DeMay RM,. The art & science of cytopathology. Chicago: ASCP Press; 1995. p 263-264.
2. Fetsch PA, Andrea A,. Immunocytochemistry in effusion cytology. Cytopathology 2001; 93: 293-308.
3. Behrens J,. Cell contacts, differentiation, and invasiveness of epithelial cells. Invasion Metastasis 1994; 14: 61-70.
4. Schofield K, D'Aquila T, Rimm DL,. E-cadherin expression is a sensitive and specific method for detection of carcinoma cells in fluid specimens. Diagn Cytopathol 2000; 22: 263-267. (Pubitemid 30220197)
5. Simsir A, Fetsch P, Mehta D, et al. E-cadherin, N-cadherin, and caltrtinin in pleural effusions: The good, the bad, the worthless. Diagn Cytopathol 1999; 20: 125-130.
6. Han J, Kim MK, Nam SJ, et al. E-cadherin and cytokeratin subtype profiling in effusion cytology. J Korean Med Sci 2004; 19: 826-833. (Pubitemid 40104875)
7. Ordonez NG,. The immunohistochemical diagnosis of mesothelioma: Differentiation of mesothelioma and lung adenocarcinoma. Am J Surg Pathol 1989; 13: 276-291. (Pubitemid 19104154)
8. Zhu W, Michael CW,. WT1, monoclonal CEA. TTF1, and CA125 antibodies in the differential diagnosis of lung, breast, and ovarian adenocarcinomas in serous effusions. Diagn Cytopathol 2007; 35: 370-375. (Pubitemid 46835030)
9. De Leij L, Poppema S, Klein Nulend J, et al. Immunoperoxidase staining on frozen tissue sections as a first screening assay in the preparation of monoconal antibodies directed against small cell carcinoma of the lung. Eur J Cancer Clin Oncol 1984; 20: 123-128. (Pubitemid 14224366)
10. Richard LM, Barry RDY, Violeta RM,. MOC-31 aids in the differentiation between adenocarcinoma and reactive mesothelial cells. Cancer 1999; 87: 390-394.
11. Lozano MD, Panizo A, Toledo GR, et al. Immunocytochemistry in the differential diagnosis of serous effusions: A comparative evaluation of eight monoclonal antibodies in papanicolaou stained smears. Cancer 2001; 93: 68-72.
12. Lyons-Boudreaux V, Mody DR, Zhai J, et al. Cytologic malignancy versus benignancy: How useful are the "newer" markers in body fluid cytology? Arch Pathol Lab Med 2008; 132: 23-28.
13. Monoclonal mouse anti-human epithelial antigen, clone Ber-EP4 package insert. CA: Dako corporation; 1998.
14. Takeshima Y, Amatya VJ, Kushitani K, et al. A useful antibody panel for differential diagnosis between peritoneal mesothelioma and ovary serous carcinoma in Japanese cases. Am J Clin Pathol 2008; 130: 771-779.
15. Kaufmann O, Dietel M,. Thyroid transcription factor-1 is the superior immunohistochemical marker for pulmonary adenocarcinomas and large cell carcinomas compared to surfactant proteins A and B. Histopathology 2000; 36: 8-16. (Pubitemid 30055417)
16. Fetsch PA, Abati A, Hijazi Y,. Utility of the antibodies CA19-9. HBME-1, and thrombomodulin in the diagnosis of malignant mesothelioma and adenocarcinoma in cytology. Cancer Cytopathol 1998; 84: 101-108. (Pubitemid 28275335)
17. Oates J, Edwards C,. HBME-1. MOC-31, WT-1, and calretinin: An assessment of recently described marker for mesothelioma and adenocarciona. Histopathology 2000; 36: 341-347.
18. Ordonez NG,. Role of immunohistochemisty in differentiating epithelial mesothelioma from adenocarcinoma. Am J Clin Pathol 1999; 112: 75-89. (Pubitemid 30214739)
19. Ordonez N,. Value of calretinin immunostaining in differentiating epithelial mesothelioma from lung adenocarcinoma. Mod Pathol 1998; 11: 929-933. (Pubitemid 28487209)
20. Chhieng DC, Yee H, Schaefer D, et al. Calretinin staining pattern aids in the differentiation of mesothelioma from adenocarcinoma in serous effusions. Cancer 2000; 90: 194-200. (Pubitemid 30438953)
21. Shield PW, Koivurinne K,. The value of calretinin and cytokeratin 5/6 as markers for mesothelioma in cell block preparations of serous effusions. Cytopathology 2008; 19: 218-223. (Pubitemid 351952108)
22. Ordonez NG,. In search of a positive immunohistochemical marker for mesothelioma: An update. Adv Anat Pathol 1998; 5: 53-59.
23. Saad RS, Lindner JL, Lin X, et al. The diagnostic utility of D2-40 for malignant mesothelioma versus pulmonary carcinoma with pleural involvement. Diagn Cytopathol 2006; 34: 801-806. (Pubitemid 44904278)
24. Yazi ji H, Battifora H, Barry TS, et al. Evaluation of 12 antibodies for distinguishing epithelioid mesothelioma from adenocarcinoma: Identification of a three-antibody immunohistochemical panel with maximal sensitivity and specificity. Mod Pathol 2006; 19: 514-523.
25. Saleh HA, Ei-Fakharany M, Makki H, et al. Differentiating reactive mesothelial cells from metastatic adenocarcinoma in serous effusions: The utility of immunocytochemical panel in the differential diagnosis. Diagn Cytopathol 2009; 37: 324-332.
26. Hanna A, Pang Y, Bedrossian CW, et al. Podoplanin is a useful marker for identifying mesothelioma in malignant effusions. Diagn Cytopathol 2010; 38: 264-269.
27. Kachali C, Eltoum I, Horton D, et al. Use of mesothelin as a marker for mesothelial cells in cytologic specimens. Semin Diagn Pathol 2006; 23: 20-24. (Pubitemid 44415394)
28. Ordonez NG,. Value of mesothelin immunostaining in the diagnosis of mesothelioma. Mod Pathol 2003; 16: 192-197. (Pubitemid 36337423)
29. Kimura N, Dota K, Araya Y, et al. Scoring system for differential diagnosis of malignant mesothelioma and reactive mesothelial cells on cytology specimens. Diagn Pathol 2009; 37: 885-890.
30. Cakir E, Demirag F, Aydin M, et al. Cytopathologic differential diagnosis of malignant mesothelioma, adenocarcinoma and reactive mesothelial cells: A logistic regression analysis. Diagn Cytopathol 2009; 37: 4-10.
31. Hasten F, Lin GY, Weidner N, et al. The use of immunohistochemistry to distinguish reactive mesothelial cells from malignant mesothelioma in cytologic effusions. Cancer Cytopathol 2010; 18: 90-96.
32. Shen J, Pinkus GS, Deshpande V, et al. Usefulness of EMA. GLUT-1, and XIAP for the cytologic diagnosis of malignant mesothelioma in body cavity fluids. Am J Clin Pathol 2009; 131: 516-523.